Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Market Closed 03-20 16:00:00 EDT

1.56

-0.06

-3.70%

盘后1.55

-0.01-0.63%

19:32 EDT

High1.62	Low1.52	Vol6.68M
Open1.62	D1 Closing1.62	Amplitude6.48%
Mkt Cap660.94M	Tradable Cap652.08M	Total Shares423.68M
T/O10.35M	T/O Rate1.60%	Tradable Shares418.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.56,"timestamp":1774036800000,"preClose":1.62,"halted":0,"volume":6680626,"hourTrading":{"tag":"盘后","latestPrice":1.5501,"preClose":1.56,"latestTime":"19:32 EDT","volume":789637,"amount":1231665.576,"timestamp":1774049559892,"change":-0.0099,"changeRate":-0.006346,"amplitude":0.006346},"delay":0,"changeRate":-0.03703703703703707,"floatShares":418000000,"shares":423680611,"eps":-0.13866,"marketStatus":"Market Closed","change":-0.06,"latestTime":"03-20 16:00:00 EDT","open":1.62,"high":1.62,"low":1.515,"amount":10347319.6471048,"amplitude":0.064815,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.13866,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.62,"preHourTrading":{"tag":"盘前","latestPrice":1.59,"preClose":1.62,"latestTime":"09:22 EDT","volume":720,"amount":1159.1379359999999,"timestamp":1774012969244,"change":-0.03,"changeRate":-0.018519,"amplitude":0.036852},"postHourTrading":{"tag":"盘后","latestPrice":1.5501,"preClose":1.56,"latestTime":"19:32 EDT","volume":789637,"amount":1231665.576,"timestamp":1774049559892,"change":-0.0099,"changeRate":-0.006346,"amplitude":0.006346},"volumeRatio":3.952299688520836,"impliedVol":1.0986,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2619153251","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619153251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619153251?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:40","pubTimestamp":1773333608,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rapid Micro Biosystems (RPID – Research Report), Lexicon Pharmace...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","LU0128526141.USD","BK4137","BK4581","LXRX","HCSG","BK4139","RPID","BK4585","LU0029874061.USD","WHWK","BK4121","XBI","XLV","LABU","BK4539"],"gpt_icon":0},{"id":"2618942438","title":"Lexicon announces results from post hoc analysis on data of sotagliflozin","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942438?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:17","pubTimestamp":1773231437,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4007","BK4139"],"gpt_icon":0},{"id":"2618442219","title":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618442219","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618442219?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:02","pubTimestamp":1773230577,"startTime":"0","endTime":"0","summary":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference               Lexicon will present results from a post hoc analysis of sotagliflozin in type 1 diabetes as a short oral pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL90jCBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","IE00B64PRP62.GBP","LXRX","NDAQ","BK4139","BK4112","SG9999014005.SGD","BK4007","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","BK4585","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","SG9999014021.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2618695106","title":"Lexicon Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2618695106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618695106?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 11:02 ET (15:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4007"],"gpt_icon":0},{"id":"2618665934","title":"Lexicon price target raised to $2.30 from $2.10 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2618665934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618665934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:53","pubTimestamp":1773140016,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz raised the firm’s price target on Lexicon (LXRX) to $2.30 from $2.10 and keeps a Buy rating on the shares. Published...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-2-30-from-2-10-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-2-30-from-2-10-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX","BK4007"],"gpt_icon":0},{"id":"2618605252","title":"Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2618605252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618605252?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:14","pubTimestamp":1773101669,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (($LXRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Lexicon Pharmaceuticals’ latest earni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-signals-leaner-path-to-key-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-signals-leaner-path-to-key-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LXRX"],"gpt_icon":0},{"id":"2617636891","title":"Leerink Partners Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636891?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:36","pubTimestamp":1772807788,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst reiterated a Hold rating on Lexicon Pharmaceuticals today and set a price target of $1.00. In addition to Leerink Partners...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-hold-rating-for-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-hold-rating-for-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"gpt_icon":0},{"id":"2617524999","title":"Lexicon Pharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617524999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617524999?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:49","pubTimestamp":1772729340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 11:49 ET (16:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"gpt_icon":0},{"id":"2617521761","title":"Lexicon price target raised to $6 from $4 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2617521761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617521761?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:06","pubTimestamp":1772726790,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Lexicon (LXRX) to $6 from $4 and keeps a Buy rating on the shares following the Q4 report. The fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-6-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-6-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX","BK4007"],"gpt_icon":0},{"id":"2617417015","title":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2617417015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617417015?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:07","pubTimestamp":1772712435,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewBiopharmaceutical firm's Q4 revenue decreased significantly compared to last yearNet loss for Q4 narrowed to $15.5 mln from $33.8 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4139","LXRX","VTRS","BK4588","BK4585","BK4583","LU2087621335.USD","BK4007"],"gpt_icon":0},{"id":"2617416905","title":"Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617416905","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617416905?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712014,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51061649/lexicon-pharmaceuticals-q4-eps-0-04-beats-0-07-estimate-sales-5-493m-beat-3-142m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"gpt_icon":0},{"id":"2617418035","title":"BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2617418035","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617418035?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711985,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04\n\n\nMar 05 (Reuters) - Lexicon Pharmaceuticals Q4 operating income USD -14.78 million.\n\nQ4 product revenue USD 1.055 million\nQ4 basic EPS USD -0.04\nQ4 net income USD -15.53 million\nQ4 operating expenses USD 20.273 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEE7ACB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LXRX"],"gpt_icon":0},{"id":"2617054189","title":"Lexicon posts Q4 net loss of USD 15.5 million (54.0% narrower)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617054189","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617054189?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711967,"startTime":"0","endTime":"0","summary":"Lexicon reported Q4 FY2025 total revenues of USD 5.5 million . Q4 R&D expenses were USD 11.3 million  and SG&A expenses were USD 8.8 million . Q4 net loss was USD 15.5 million, or USD 0.04 per share. For FY2025, total revenues were USD 49.8 million , R&D expenses were USD 61.1 million , SG&A expenses were USD 37.3 million , and net loss was USD 50.3 million . Cash, investments and restricted cash totaled USD 125.2 million as of Dec. 31, 2025. On the business side, Lexicon said enrollment in the pivotal SONATA-HCM Phase 3 trial of sotagliflozin has surpassed 50%, with enrollment completion expected in mid-2026 and topline results in Q1 2027. The company said it remains on track for a potential 2026 NDA resubmission for sotagliflozin in type 1 diabetes, contingent on meeting FDA-identified exposure and safety data requirements via the STENO1 study. Lexicon also reported a positive FDA End-of-Phase 2 meeting for pilavapadin  in diabetic peripheral neuropathic pain, with no objections to a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL5RsxTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","BK4585","BK4007","SG9999014039.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4112","LU2210149790.SGD","LXRX","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2617541858","title":"Lexicon Pharmaceuticals Q4 Operating Expenses USD 20.273 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541858?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEE7ACB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LXRX","BK4139"],"gpt_icon":0},{"id":"2617541832","title":"Lexicon Pharmaceuticals Q4 Operating Income USD -14.78 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541832?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEE7ACB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","LXRX"],"gpt_icon":0},{"id":"2617542199","title":"Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542199?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711940,"startTime":"0","endTime":"0","summary":"Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3249981/0/en/Lexicon-Pharmaceuticals-Reports-Fourth-Quarter-2025-Financial-Results-and-Provides-Clinical-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","IE00BZ1G4Q59.USD","LU0154236417.USD","HCM","BK4585","BK4588","NVOX","BK4531","BK4139","LU1093756168.USD","IE00BKVL7J92.USD","LU1093756325.SGD","LXRX","IND","BK4599","NVOH"],"gpt_icon":1},{"id":"2616371984","title":"Lexicon Pharmaceuticals to Join Leerink Partners Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371984","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371984?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:01","pubTimestamp":1772571676,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals to Join Leerink Partners Global Healthcare Conference Fireside Chat               Lexicon Pharmaceuticals Inc. management will participate in a fireside chat at the 2026 Leerin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL8cq7TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","MNSH","SG9999014005.SGD","LXRX","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","BK4112","BK4207","BK4585","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4588","NDAQ","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139"],"gpt_icon":0},{"id":"2616325169","title":"Lexicon Pharmaceuticals Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325169","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325169?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:04","pubTimestamp":1772546644,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc  expected to post a loss of7cents a share - Earnings Preview Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to  show a fall in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR1SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX","BK4007"],"gpt_icon":0},{"id":"2614859812","title":"Lexicon Pharmaceuticals Director Raymond Debbane Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859812","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859812?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:33","pubTimestamp":1772199232,"startTime":"0","endTime":"0","summary":"Raymond Debbane, a director, reported an acquisition of 2,000 common shares of Lexicon Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7GWw8W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Lexicon Pharmaceuticals Director Raymond Debbane Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LXRX"],"gpt_icon":0},{"id":"2614704247","title":"Lexicon Pharmaceuticals Inc. to Report Fourth-Quarter 2025 Financial Results and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2614704247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614704247?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:31","pubTimestamp":1772112700,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. to Report Fourth-Quarter 2025 Financial Results and Host Conference Call               Lexicon Pharmaceuticals Inc. will release its fourth quarter 2025 financial results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLyssQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BKPKM429.USD","LXRX","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","SG9999014005.SGD","NDAQ","BK4007","BK4585","LU2210149790.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":0.1818},{"period":"3month","weight":0.3333},{"period":"6month","weight":0.3109},{"period":"1year","weight":3.5231},{"period":"ytd","weight":0.3565}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.44,"avgChangeRate":0.012763},{"month":5,"riseRate":0.5,"avgChangeRate":0.029091},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}